Sign In
Last checked at 
24 Jun 2026 17:18
24 June 2026
GenIP Plc
("GenIP" or the "Company")
Result of AGM
GenIP Plc (AIM: GNIP), a technology consultancy providing AI-driven services to help research organisations and corporations commercialise their innovations, is pleased to announce that at the Company's Annual General Meeting ("AGM") held earlier today all resolutions were duly passed.
The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:
Resolution | For | % Votes Cast | Against | % Votes Cast | Votes Withheld | Total Votes Cast |
(1) Approval of the Annual Report and Accounts | 13,034,359 | 99.95 | 6,657 | 0.05 | 1,000 | 13,041,016 |
(2) Re-appoint HW Fisher LLP as auditor of the Company | 13,013,071 | 99.79 | 27,945 | 0.21 | 1,000 | 13,041,016 |
(3) Authorise the Directors to determine the auditor's remuneration | 12,884,866 | 98.8 | 156,150 | 1.2 | 1,000 | 13,041,016 |
(4) Re-elect Lord David Willetts as a Director of the Company | 12,634,053 | 97.23 | 359,960 | 2.77 | 48,003 | 12,994,013 |
(5) Re-elect Melissa Cruz as a Director of the Company | 12,706,872 | 97.79 | 287,141 | 2.21 | 48,003 | 12,994,013 |
(6) Re-elect Kevin Fitzpatrick as a Director of the Company | 12,634,053 | 97.23 | 359,960 | 2.77 | 48,003 | 12,994,013 |
(7) Re-elect Professor David Gann CBE as a Director of the Company | 12,706,872 | 97.79 | 287,141 | 2.21 | 48,003 | 12,994,013 |
(8) To authorise the Directors to allot shares, up to an aggregate nominal amount equal to £54,224.60 | 12,634,105 | 96.89 | 405,908 | 3.11 | 2,003 | 13,040,013 |
(9) To authorise the Directors to disapply pre-emption rights in respect of a rights issue and otherwise up to an aggregate nominal amount equal to £54,224.60 | 12,634,105 | 96.89 | 405,908 | 3.11 | 2,003 | 13,040,013 |
1. Proxy appointments which gave discretion to the Chairman of the AGM have been included in the "For" total for the appropriate resolution.
2. Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.
3. A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against".
4. The full text of the resolutions passed at the AGM can be found in the Notice of Annual General Meeting which is available on the Company's website at http://genip.ai/.
As at 24 June 2026, there were 25,517,461 ordinary shares in issue. Shareholders are entitled to one vote per share.
Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
For further information regarding GenIP, please visit www.genip.ai, or contact:
GenIP Plc Melissa Cruz, CEO | Via Redchurch Communications | |
Beaumont Cornish Limited (Nominated Adviser) Roland Cornish / Asia Szusciak / Andrew Price
| Tel: +44 (0) 20 7628 3396
| |
AlbR Capital Limited (Broker) Colin Rowbury Jon Belliss
|
| Tel: +44 (0)20 7399 9427 cr@albrcapital.com Jb@albrcapital.com
|
CMC Markets (Joint Broker) | Tel: + 44 (0) 203 003 8632 | |
Douglas Crippen | ||
| ||
Redchurch Communications (Financial PR) John Casey
| genip@weareredchurch.com
|
Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.
Notes to Editors
About GenIP
GenIP is a next-generation business at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.
Service Offerings
GenIP operates through two synergistic service lines:
Service | Description | Value Proposition |
Invention Intelligence Product Suite | AI-powered market intelligence reports assessing the commercial potential of emerging technologies | Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy |
IP Commercialization Services
| End-to-end engagement to help research organisations commercialise innovations
| Provides cost-effective, broad support to achieve our clients' strategic objectives
|
Together, these services form a unified GenAI-enabled platform for innovation triage and execution.
Vision & Strategy
GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:
● Organic ExpansionScale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.
● Service DeepeningEnhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.
● Strategic AcquisitionsPursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.
Forward looking statements
Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.
Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".
For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.
-ENDS-
Follow the stocks
